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A selective chromogenic culture media for the laboratory isolation and differentiation of colistin resistant Acinetobacter, Pseudomonas, Stenotrophomonas and Enterobacteriaceae spp. (CHROMagar COL-APSE) was developed, evaluated and compared to an existing selective bacterial culture medium (SuperPolymyxin). 

Methodology
Media were challenged with eighty-four isolates including polymyxin B (POL B) susceptible and resistant type strains and colistin (COL) resistant organisms recovered from human and animal samples. Susceptibility to COL and POL B was determined by agar dilution and broth microtitre dilution. The lower limit for the detection of COL resistant organisms was also calculated for both CHROMagar COL-APSE and SuperPolymyxin media. The ability to isolate and correctly differentiate COL resistant organisms within mixed cultures was also assessed and compared using both media. 
 
Results
Using CHROMagar COL-APSE, Gram-negative pathogens (n=71) with intrinsic (n=8) or acquired COL (n=63) resistance were recovered with 100 % specificity down to the lower limit of detection of 101 CFU (Colony Forming Units).  Growth on SuperPolymyxin was similar, but notably weaker for COL resistant non-fermentative bacteria (Acinetobacter, Pseudomonas, Stenotrophomonas). CHROMagar COL-APSE was also more sensitive in supporting growth of Enterobacteriaceae with COL resistance associated with the carriage of mcr-1.    
Conclusion





Polymyxin B and E (colistin) are increasingly used in the treatment of multi-drug resistant bacterial infections. Both are cationic polypeptides that bind the lipopolysaccharides (LPS) of Gram-negative bacteria and disrupt the outer membrane. Polymyxin resistance (PR), although intrinsic amongst Gram-positive and some Gram-negative species (Proteus, Morganella, Serratia spp.), is an emerging problem in a number of other pathogens (Acinetobacter baumannii, Pseudomonas aeruginosa, Escherichia coli, Salmonella enterica, Klebsiella pneumoniae). Resistance can occur due to mutations / insertions in genes involved in LPS biosynthesis (lpx, pmrA/B, mgrB, phoP/Q) and / or can be acquired by the horizontal transmission of genes encoding phosphoethanolamine transferase (pEtN) enzymes. Plasmid mediated colistin (COL) resistance due to the mcr-1 pEtN gene was recently identified in China [1]. Since it was first described, bacteria producing MCR-1 have been found in a wide range of food producing animals, human and environmental sources. Moreover, MCR-1 producing isolates are often pan (PDR) or extensively (XDR) drug resistant, which significantly limits the therapeutic options for these organisms. 

A sensitive and specific means for the isolation of PR organisms is critical for any strategy aimed at monitoring the spread of these isolates and identifying new resistance determinants. Furthermore, polymyxin resistance may often be low level or unstable (heteroresistance), and there are well established difficulties (e.g., cation concentrations in broth, adsorption of colistin to plastics, poor diffusion in agar) in the accurate determination of COL MICs [2]. Molecular detection is limited to the small number of mutations (mcr-1 – 1.8) and MCR-like alleles (mcr-2, mcr-3, mcr-4) discovered to date [1, 3]. 






CHROMagar COL-APSE plates were prepared in-house using dehydrated CHROMagar base media (CHROMagarTM, Paris, France) supplemented as in Table 1 with the CHROMagar COL-APSE supplement (X192). This contains antimicrobials (colistin sulfate / oxazolidonones) at concentrations designed to enhance the growth of PR Gram-negative species, suppress the growth of Gram-positive bacteria, whilst avoiding significant synergy between the active compounds. This medium was not autoclaved, but instead sterilized by boiling at 100 °C in order to preserve the chromogenic compounds included in the mixture, prior to the addition of all supplements. All additional antibiotics used (colistin sulfate, polymyxin B, daptomycin, amphotericin B) were sourced from Sigma-Aldrich (Gillingham, UK) or Cambridge Bioscience (Cambridge, UK) and prepared as stock solutions (10,000 µg/ml – 100 µg/ml) in distilled water. Those containing COL or polymyxin B (POL B) were handled only in glass tubes and used within 24 hrs. SuperPolymyxin plates were prepared exactly as described by Nordmann et al [4] using EMB manufactured by Thermo Fisher Oxoid (Basingstoke, UK). CHROMagar COL-APSE media for use with samples containing Proteus spp. were prepared with the addition of 50 mg/L p-nitrophenyl glycerol (PNPG). 

Bacterial isolates and Determination of Polymyxin Minimum Inhibitory concentrations (MICs)
Eighty-four isolates were used in the evaluation of CHROMagar COL-APSE media (Table 2). These included  8 isolates with intrinsic COL resistance (1 clinical human and 7 type strains), 13 COL susceptible isolates (6 human clinical, 3 veterinary clinical and 4 type strains) and 63 isolates with acquired COL resistance (5 human clinical and 58 veterinary clinical) contained within our collections. 

The MICs of COL and POL B (0.006 – 256 µg/ml) were determined for each isolate by agar dilution on Mueller-Hinton II (MH 2) agar [5]. Plates were seeded with 104 CFU using a multi-point inoculator and examined for growth after incubation at 37 °C for 18 hrs. Susceptibility (≤ 2-4 µg/ml) and resistance (> 2-8 µg/ml) to either COL or POL B were interpreted according to current CLSI and / or EUCAST species specific breakpoints where available [6, 7]. Susceptibility to COL was also determined by broth microtitre dilution (BMD) to enable the MICs to be compared to those obtained  on solid media.    

All clinical isolates were additionally screened for the presence of  mcr related genes by PCR using CLR5-F (5ʹ-CGGTCAGTCCGTTTGTTC-3ʹ), CLR5-R (5ʹ-CTTGGTCGGTCTGTAGGG-3ʹ), MCR2-F (5’-TGGTACAGCCCCTTTATT-3’) and MCR2-R (5’-GCTTGAGATTGGGTTATGA-3’) primers for the detection of mcr-1-1.8 and mcr-2 , respectively [1, 3]. 

Comparative Growth on Selective Media
The ability of CHROMagar COL-APSE and SuperPolymyxin to support or suppress growth was first assessed using a fixed inoculum of 103 CFU of each strain. Overnight cultures were used to prepare a 0.5 McFarland standard (1.5 x 108 CFU) further diluted in 0.85% saline (OXOID, United Kingdom) and used to inoculate supplemented and un-supplemented CHROMagar and SuperPolymyxin (EMB) base plates.
Lower Limit of Detection (LLD)  
Sensitivity was compared by determining the lowest number (CFU) of COL resistant bacteria in the inocula required for growth on each media. The lowest limit of detection (LLD) was assessed using serial dilutions (10-1 – 10-9) of overnight cultures grown at 37 °C for 24 h in 3 ml of Luria-Bertani (LB) broth. Ten-fold serial dilutions were made in 0.85 % saline (volume / volume) and 20 μl of each dilution plated onto unsupplemented MH 2 (control), CHROMagar COL-APSE and SuperPolymyxin agar plates using the Miles and Misra procedure [11]. Following incubation for 24 h at 37°C, colonies were counted and the number of bacteria recovered expressed as colony forming units per ml (CFU/ml). Colony counts after incubation on CHROMagar COL-APSE and SuperPolymyxin agar were subtracted from the number recovered on MH 2 agar to quantify the total number of COL resistant organisms (CFU) within the population plated required for viable growth on each selective media (LLD).

Isolation and Differentiation of Organisms in Mixed Culture
Two pools containing mixtures of COL resistant (R) and COL susceptible (S) organisms were used to assess the performance of the media with complex polymicrobial samples. Pool one consisted of Proteus mirabilis NCTC 13376, A. baumannii AB205 (COL R), E. coli E7 (COL R), E. cloacae NCTC 10005 (COL R), E. faecalis ATCC 2912 (COL R), K. pneumoniae KP19 (COL R), M. morgannii MM2 (COL R), S. marcescens NCTC 10211 (COL R) and P. aeruginosa ATCC 27853 (COL heteroresistant). Pool two consisted of A. baumannii ATCC 19606 (COL S), E. coli ATCC 25922 (COL S), E. faecalis ATCC 2912 (COL R), P. aeruginosa ATCC 27853 (COL heteroresistant) and K. pneumoniae ATCC 9633 (COL S).   Pools were made by mixing single colonies of each isolate in 3 ml 0.85% saline adjusted to a 0.5 McFarland standard (1.5 x 108 CFU/ml), confirmed by viable colony counts. Further dilutions were made to achieve a concentration of 105 CFU/ml and CHROM-agar COL-APSE plates then inoculated with 10 µl (103 CFU), either spread across the entire plate using a L-shaped spreader, or by streaking across the plate using a 10 µl loop   (Figure 2).  





The in-vitro activity (MIC mg/L) of both COL and POL B when determined by agar dilution was comparable (+/- 1 dilution) for all Enterobacteriaceae isolates tested (Table 2). However the MICs of COL and POL B differed by at least three dilutions for S. maltophilia NCTC 10258 and A. baumannii AB205. The mcr-1 gene was present in 61 of the E. coli, 58 (95 %) of which were also phenotypically resistant to COL (MIC >2 µg/ml). Three isolates containing mcr-1 had colistin MICs below the pharmacodynamic breakpoint when the MIC was determined by agar dilution. Three COL resistant A. baumannii and 2 K. pneumoniae (MIC 8 - >256 µg/ml) clinical isolates were also identified and included in the evaluation of both media. The mechanism of resistance in these three strains is yet to be determined, despite sequencing for mutations in mgrB, pmrA/B and the phoP/Q regulatory genes known previously to be associated with mutational polymyxin resistance [8]. When susceptibility to COL was determined by BMD, the MIC of COL was comparable to that determined by agar dilution (+/- 1 dilution vs all strains).


Growth on CHROMagar COL-APSE on plates inoculated with 103 CFU was observed for all COL R Gram-negative isolates. All the COL susceptible Enterobacteriaceae, COL resistant Gram-positive (Enterococci spp) and fungal (Candida spp) isolates failed to grow at these inocula (Figure1). Growth of the P. aeruginosa ATCC 27853 type strain (COL MIC 2 µg/ml) however, was supported on CHROMagar COL-APSE at 103 CFU. Although this isolate is deemed susceptible to COL according to current CLSI breakpoints, and recommended as a control strain for antimicrobial susceptibility testing, it should be noted that it has frequently been shown to exhibit heteroresistance to COL in-vitro when population analysis profiling (PAP) is used as the gold standard [9]. The -70°C stock of ATCC 27853 held in our laboratory used in this study consistently demonstrates heteroresistance to COL when assessed using the PAP method. 
  
Growth on SuperPolymyxin media with an inocula of 103 CFU was similar, but visibly weaker for each of the COL resistant non-fermenters. Growth of one strain of COL resistant A. baumannii (MIC 8 µg/ml) and S. maltophilia (MIC 32 µg/ml) were not supported at all (Figure 1). It is possible that antimicrobial synergy known to exist between COL and daptomycin against A. baumannii [10] could account for the poor growth or inhibition of these species that we observed on SuperPolymyxin agar. In contrast to growth on SuperPolymyxin, the chromogenic properties of the CHROMagar COL-APSE media enabled clear differentiation of COL resistant Enterobacteriaceae from non-fermenters. Phenotypic identification as either dark pink to reddish (E. coli), metallic blue (Klebsiella, Enterobacter, Serratia spp) or colourless, natural pigmentation (Morganella) was also possible whilst on SuperPolymyxin, only COL resistant E. coli could be identified by their metallic green appearance. In the limit of detection studies COL resistant strains could be recovered on both media at 101 CFU whilst growth of strains deemed susceptible to COL was only possible using an inocula of >104 (Table 1). 







We found both CHROMagar COL-APSE and the SuperPolymxin media were able to support the growth of COL resistant Gram-negative bacteria whilst suppressing COL resistant Gram-positive pathogens. Using clinical isolates, CHROMagar COL-APSE supported the growth of all COL resistant strains down to an inocula as low as 101 CFU. Growth with an inocula of 101 CFU was also supported on SuperPolymyxin, but only for 50/58 (86%) of the E. coli isolates with COL resistance accompanied by mcr-1, suggesting it may have slightly lower sensitivity in the detection of these strains (Table 2). SuperPolymyxin however was found to be better (≥1 dilution) in suppressing the growth of COL susceptible Salmonella spp. Reduced susceptibility to polymyxins in Salmonella Enteritidis and other serogroup 9 strains has been reported and the epidemiological cut-off (> 2 mg/L) for resistance challenged [12]. As the mechanisms for reduced susceptibility reported in Salmonella spp remain unknown, a more sensitive medium may help in the recovery of COL resistant strains and aid in elucidation of alternative resistance mechanisms.

The only other difference we observed between the two media (Table 2) was differential growth of P. aeruginosa ATCC 27853 on CHROMagar COL-APSE (LLD = 102 CFU) when compared to SuperPolymyxin (LLD 105 = CFU). Again this may represent the heteroresistant properties of this strain and a high frequency of COL resistance by spontaneous mutation. As with A. baumannii, synergy between the selective antimicrobials in the media may be responsible for the differential ability of CHROMagar COL-APSE and SuperPolymyxin to identify heteroresistant strains. The clinical relevance of heteroresistance to polymyxins is unclear, although the ability to easily identify such strains may be useful in optimizing or selecting COL based therapies on an individual basis.   

Notably, addition of PNPG was beneficial in suppressing swarming of colistin resistant Proteus spp without affecting the performance of the media. This provides a more robust method to select out COL resistant isolates within mixed specimens.
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        Sterilize by heating to 100 °C  CHROMagar growth supplement S1			2 ml
CHROMagar COL-APSE Supplement (X192)	 	 	4 ml
	








Table 2. Characteristics of Bacterial Isolates
Isolate	MIC (mg/L)/ Agar dilution	Polymyxin Resistance Mechanism 	Lowest Limit of Detection (CFU)
 	Colistin	Polymyxin B		CHROMagar COL-APSE	SuperPolymyxin 
Intrinsic Resistance to Polymyxins	 	 	 	 	 
                  P. mirabilis NCTC 13376	>256	>256	Intrinsic	10 1	10 1
                  S. marcescens NCTC 10211	>256	>256	Intrinsic	10 1	10 1
M. morgannii MM2	>256	>256	Intrinsic	10 1	10 1
E. faecalis ATCC 2912 	>256	256	Intrinsic	>10 9	>10 9
E. gallinarum ATCC 49573	>256	>256	Intrinsic	>10 8	>10 8
C. albicans ATCC 10231	256	256	Intrinsic	>10 7	>10 7
E. cloacae NCTC 10005 	128	256	Intrinsic	10 2	10 1†
S. maltophilia NCTC 10258	8	64	Intrinsic	10 1*	10 2
Susceptible to Polymyxins	 	 	 	 	 
P. aeruginosa ATCC 27853 	2	2	NA	10 2*	10 5
Salmonella enterica Group D (non-Typhi) Sal3	2	2	N/A	10 4*	10 6
E. coli E17	1	2	MCR-1	10 7	10 7
Salmonella enterica subsp. diarizonae Sal1	1	2	N/A	10 5*	10 6
A. baumannii ATCC 19606	1	2	NA	10 6	10 6
E. coli E44	1	1	MCR-1	>10 9	>10 9
Salmonella enterica subsp. diarizonae Sal4	1	1	N/A	10 5*	10 6
K.  pneumoniae KP32	0.5	1	NA	10 6	10 6
Salmonella enterica subsp. diarizonae Sal2	0.5	1	N/A	10 5*	10 6
Salmonella enterica Group D (non-Typhi) Sal5	0.5	1	N/A	10 3*	10 5
E. coli ATCC 25922	0.5	0.5	NA	10 6	10 6
E. coli 408756	0.5	0.5	MCR-1	10 6	10 6
K. pneumoniae ATCC 9633	0.5	0.5	NA	>10 9*	10 5
Acquired Resistance to polymxins	 	 	 	 	 
A. baumannii  AB219	>256	>256	Unknown	10 1	10 1
A. baumannii AB205	>256	32	Unknown	10 1	10 1
A. baumannii AB287	8	4	Unknown	10 1*	10 2
K. pneumoniae KP6	128	256	Unknown	10 1	10 1
K. pneumoniae KP19	64	64	Unknown	10 1	10 1
E. coli 35095	>256	>256	MCR-1	10 1	10 1
E. coli 35175	64	32	MCR-1	10 1	10 1
E. coli 29881	32	32	MCR-1	10 1	10 1
E. coli 33907	32	32	MCR-1	10 1	10 1
E. coli 34936	32	32	MCR-1	10 1	10 1
E. coli 35593	32	32	MCR-1	10 1	10 1
E. coli E10	32	16	MCR-1	10 1*	10 4
E. coli E9	32	16	MCR-1	10 1	10 1
E. coli E33	32	16	MCR-1	10 1	10 1
E. coli E3	32	16	MCR-1	10 1	10 1
E. coli E1	32	16	MCR-1	10 1	10 1
E. coli E35	32	16	MCR-1	10 1	10 1
E. coli E29	32	16	MCR-1	10 1	10 1
E. coli E32	32	16	MCR-1	10 1	10 1
E. coli E13	32	16	MCR-1	10 1	10 1
E. coli E24	32	16	MCR-1	10 1	10 1
E. coli E20	32	16	MCR-1	10 1	10 1
E. coli E25	32	16	MCR-1	10 1	10 1
E. coli E27	16	32	MCR-1	10 1	10 1
E. coli E8	16	16	MCR-1	10 1	10 1
E. coli E11	16	16	MCR-1	10 1*	10 2
E. coli E39	16	16	MCR-1	10 1	10 1
E. coli E40	16	16	MCR-1	10 1	10 1
E. coli E34	16	16	MCR-1	10 1	10 1
E. coli E2	16	16	MCR-1	10 1	10 1
E. coli 412049521	16	16	MCR-1	10 1	10 1
E. coli E37	16	16	MCR-1	10 1	10 1
E. coli E41	16	16	MCR-1	10 1	10 1
E. coli E36	16	16	MCR-1	10 1	10 1
E. coli E31	16	16	MCR-1	10 1	10 1
E. coli E30	16	16	MCR-1	10 1*	10 3
E. coli E14	16	16	MCR-1	10 1	10 1
E. coli E12	16	16	MCR-1	10 1	10 1
E. coli 14042624	16	16	MCR-1	10 1	10 1
E. coli 412016126	16	16	MCR-1	10 1	10 1
E. coli E22	16	16	MCR-1	10 1	10 1
E. coli E19	16	16	MCR-1	10 1	10 1
E. coli E7	16	16	MCR-1	10 1	10 1
E. coli E47	16	16	MCR-1	10 1	10 1
E. coli E49	16	16	MCR-1	10 1*	10 3
E. coli E5	16	16	MCR-1	10 1*	10 3
E. coli E16	16	16	MCR-1	10 1	10 1
E. coli E18	16	16	MCR-1	10 1	10 1
E. coli E43	16	16	MCR-1	10 1*	10 3
E. coli E46	16	16	MCR-1	10 1	10 1
E. coli E28	16	16	MCR-1	10 1	10 1
E. coli E26	16	16	MCR-1	10 1	10 1
E. coli 27852	16	16	MCR-1	10 1	10 1
E. coli 35062	16	16	MCR-1	10 1*	10 3
E. coli 37914	16	16	MCR-1	10 1	10 1
E. coli 41323	16	16	MCR-1	10 1	10 1
E. coli 41339	16	16	MCR-1	10 1	10 1
E. coli 41848	16	16	MCR-1	10 1	10 1
E. coli 412044854	16	8	MCR-1	10 1	10 1
E. coli 413040864	16	8	MCR-1	10 1	10 1
E. coli 34692	16	8	MCR-1	10 1*	10 2
E. coli E45	8	16	MCR-1	10 1	10 1
E. coli 32218	8	8	MCR-1	10 1	10 1
					
* Enhanced Sensitivity of CHROMagar COL-APSE					













Fig. 2  Growth on CHROMagar base media and CHROMagar COL-APSE of simulated pools of COL susceptible and COL resistant strains.

A: CHROMagar COL-APSE – simulated pool containing A.baumannii AB205 (COL R), E. coli E7 (COL R). E. cloacae NCTC 10005 (COL R), E. faecalis ATCC 2912 (COL R), K. pneumoniae KP19 (COL R), M. morgannii MM2 (COL R), P. aeruginosa ATCC 27853 (COL heteroresistant), S. marcescens NCTC 10211 (COL R), P. mirabilis NCTC 13376 (COL R). Plate inoculated with L-shaped spreader.

B: CHROMagar COL-APSE + 50 mg/L p-nitrophenyl glycerol (PNPG) simulated pool containing A.baumannii AB205 (COL R), E. coli E7 (COL R). E. cloacae NCTC 10005 (COL R), E. faecalis ATCC 2912 (COL R), K. pneumoniae KP19 (COL R), M. morgannii MM2 (COL R), P. aeruginosa ATCC 27853 (COL heteroresistant), S. marcescens NCTC 10211 (COL R), P. mirabilis NCTC 13376 (COL R). Plate inoculated with L-shaped spreader.

C: CHROMagar COL-APSE – simulated pool containing A.baumannii AB205 (COL R), E. coli E7 (COL R). E. cloacae NCTC 10005 (COL R), E. faecalis ATCC 2912 (COL R), K. pneumoniae KP19 (COL R), M. morgannii MM2 (COL R), P. aeruginosa ATCC 27853 (COL heteroresistant), S. marcescens NCTC 10211 (COL R), P. mirabilis NCTC 13376 (COL R). Plate inoculated by streaking method.
D: CHROMagar COL-APSE  + 50 mg/L p-nitrophenyl glycerol (PNPG) - simulated pool containing A.baumannii AB205 (COL R), E. coli E7 (COL R). E. cloacae NCTC 10005 (COL R), E. faecalis ATCC 2912 (COL R), K. pneumoniae KP19 (COL R), M. morgannii MM2 (COL R), P. aeruginosa ATCC 27853 (COL heteroresistant), S. marcescens NCTC 10211 (COL R), P. mirabilis NCTC 13376 (COL R). Plate inoculated by streaking method.

E: CHROMagar COL-APSE - simulated pool containing A.baumannii ATCC 19606 (COL S), E. coli ATCC 25922 (COL S). E. faecalis ATCC 2912 (COL R), P. aeruginosa ATCC 27853 (COL heteroresistant), K. pneumoniae ATCC 9633 (COL S). Plate inoculated with L-shaped spreader.

F: CHROMagar COL-APSE + 50 mg/L p-nitrophenyl glycerol (PNPG) - simulated pool containing A.baumannii ATCC 19606 (COL S), E. coli ATCC 25922 (COL S). E. faecalis ATCC 2912 (COL R), P. aeruginosa ATCC 27853 (COL heteroresistant), K. pneumoniae ATCC 9633 (COL S). Plate inoculated with L-shaped spreader
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